Presentation is loading. Please wait.

Presentation is loading. Please wait.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Published byJulianna Curtis Modified over 6 years ago

Similar presentations

Presentation on theme: "Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based."— Presentation transcript:

1 Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based remission. Patients were divided into 9 areas (A–I). Numbers of patients in each area were 90 for A, 1628 for B, 1742 for C, 1 for D, 144 for E, 635 for F, 1 for G, 28 for H, and 335 for I. Functions: Area A = Y ≥ and X < ; Area I = Y < and X ≥ Takao Koike et al. J Rheumatol 2014;41:15-23 ©2014 by The Journal of Rheumatology

Download ppt "Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based."

Similar presentations

The Healing Potential of Stable Juvenile Osteochondritis Dissecans Knee Lesions by Eric J. Wall, Jason Vourazeris, Gregory D. Myer, Kathleen H. Emery,

The Healing Potential of Stable Juvenile Osteochondritis Dissecans Knee Lesions by Eric J. Wall, Jason Vourazeris, Gregory D. Myer, Kathleen H. Emery,
Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-

Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Adjusted relative mortality risk

Adjusted relative mortality risk
Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).

Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).
Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.

Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.
Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Patient disposition during open-label longterm exposure period.

Patient disposition during open-label longterm exposure period.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
First-pass perfusion images through the short axis, 2-chamber views.

First-pass perfusion images through the short axis, 2-chamber views.
Percentage of patients achieving minimal disease activity (MDA): A

Percentage of patients achieving minimal disease activity (MDA): A
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.

Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.
Kenshi Hayashi et al. JACEP 2016;2:

Kenshi Hayashi et al. JACEP 2016;2:
Fundus photographs of the right (A) and left (B) eyes with intraretinal hemorrhages (white arrowheads) and perivascular sheathing of retinal veins (black.

Fundus photographs of the right (A) and left (B) eyes with intraretinal hemorrhages (white arrowheads) and perivascular sheathing of retinal veins (black.
Transmission map of P. jirovecii among outpatients with RA

Transmission map of P. jirovecii among outpatients with RA

Similar presentations

Ads by Google